IGM Biosciences Future Growth
Future criteria checks 2/6
IGM Biosciences is forecast to grow earnings and revenue by 23.2% and 54.2% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be -220.7% in 3 years.
Key information
23.2%
Earnings growth rate
30.3%
EPS growth rate
| Biotechs earnings growth | 24.6% |
| Revenue growth rate | 54.2% |
| Future return on equity | -220.7% |
| Analyst coverage | Good |
| Last updated | 24 May 2024 |
Recent future growth updates
Recent updates
IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28
IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 51 | -237 | -213 | -198 | 8 |
| 12/31/2025 | 10 | -232 | -215 | -211 | 10 |
| 12/31/2024 | 46 | -163 | -163 | -140 | 10 |
| 3/31/2024 | 2 | -237 | -195 | -184 | N/A |
| 12/31/2023 | 2 | -246 | -205 | -192 | N/A |
| 9/30/2023 | 2 | -238 | -196 | -182 | N/A |
| 6/30/2023 | 2 | -234 | -196 | -182 | N/A |
| 3/31/2023 | 2 | -229 | -29 | -18 | N/A |
| 12/31/2022 | 1 | -221 | -16 | -6 | N/A |
| 9/30/2022 | 1 | -219 | -13 | -3 | N/A |
| 6/30/2022 | 0 | -205 | -6 | 3 | N/A |
| 3/31/2022 | N/A | -185 | -146 | -136 | N/A |
| 12/31/2021 | N/A | -165 | -138 | -125 | N/A |
| 9/30/2021 | N/A | -139 | -131 | -112 | N/A |
| 6/30/2021 | N/A | -115 | -116 | -93 | N/A |
| 3/31/2021 | N/A | -95 | -101 | -79 | N/A |
| 12/31/2020 | N/A | -81 | -85 | -68 | N/A |
| 9/30/2020 | N/A | -72 | -68 | -57 | N/A |
| 6/30/2020 | N/A | -61 | -62 | -57 | N/A |
| 3/31/2020 | N/A | -53 | -56 | -53 | N/A |
| 12/31/2019 | N/A | -43 | -47 | -45 | N/A |
| 9/30/2019 | N/A | -37 | -41 | -39 | N/A |
| 6/30/2019 | N/A | -34 | -31 | -30 | N/A |
| 3/31/2019 | N/A | -27 | -26 | -24 | N/A |
| 12/31/2018 | N/A | -23 | -21 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IGMS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IGMS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IGMS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IGMS's revenue (54.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: IGMS's revenue (54.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IGMS is forecast to be unprofitable in 3 years.